Background. Currently, there are no comparable estimates of the short-term risk of disease progression in the absence of effective antiretroviral therapy for human immunodeficiency virus (HIV)-infected adults and children.
An important consideration in deciding whether to initiate antiretroviral therapy (ART) for an HIV-infected patient is the patient's short-term risk of disease progression in the absence of treatment. The key prognostic marker used to quantify this risk is the number of CD4 cells, expressed either as an absolute concentration or as a percentage of the total lymphocyte count (i.e., the CD4 cell percentage) [1] . However, clinically relevant estimates of the risk of disease progression based on the most recent immunologic assessment have only recently become available [2] [3] [4] [5] . In particular, risk estimates that are relevant to developed countries and for which informed treatment guidelines are available [6 -8] were derived from 2 large collaborative studies, one involving adults (the Concerted Action on Sero-Conversion to AIDS and Death in Europe [CASCADE] collaboration) and one involving children (the HIV Paediatric Prognostic Markers Collaborative Study [HPPMCS] ) [2] [3] [4] . However, a direct comparison of the results of the 2 analyses is precluded because of important differences in the statistical approaches of the studies. Also, both anal-yses revealed the presence of age-associated effects, independent of the CD4 cell count, that need to be taken into consideration [2] [3] [4] .
In the present study, we assessed data from both analyses by use of a common methodology, to gain a more complete picture of how, for a given CD4 cell count level, the risks of AIDS and death vary across the age range of the patients. In particular, we were interested in determining whether, for children, there is an age threshold at which the association between the CD4 cell count and the rate of disease progression approximates that noted in adults. This finding could help achieve consistency between treatment guidelines for children and adults, as well as inform age eligibility criteria for trials enrolling both children and adults.
METHODS
In the HPPMCS, which is a meta-analysis of individual patient data, information was pooled, in 2000, across 17 European and US cohort studies and trials involving children who had vertically acquired HIV infection and for whom data were available before the introduction of combination ART [3, 4] . The study includes both children who were followed from birth (after infection was diagnosed in the mother) and those whose HIV infection was detected later in life. Children in the latter group were excluded from the relevant analysis if they developed AIDS or died within 1 month of the first clinical presentation.
CASCADE is an international collaboration, established in 1997, that annually brings together data from 22 cohorts in Europe, Australia, and Canada [2] . All cohorts comprise HIVinfected persons for whom it was possible to estimate the time of HIV seroconversion, most commonly because a negative HIV antibody test result was noted a maximum of 3 years before the first positive test result was obtained. The present analysis is based on data pooled in 2004.
AIDS was defined using the clinical conditions in the 1993 Centers for Disease Control and Prevention (CDC) classification system for adults and adolescents and the 1994 CDC classification system for children (however, with the exclusion of lymphoid interstitial pneumonitis) [9, 10] . These systems differ in their definition of serious recurrent bacterial infection. For adults, such infection includes only salmonella (nontyphoid) septicemia or pneumonia. For children, the definition is broader: the infection is not organism specific, and it includes more organ systems. The cause of death was not recorded in the HPPMCS and was missing for approximately one-quarter of deaths that occurred in CASCADE [11] . Information on injection drug users was excluded from CASCADE data, because this exposure group experiences a disproportionately high number of non-HIV-related deaths [12] . Finally, to avoid an overlap between the 2 studies, all CD4 cell counts determined after patients were 15 years of age were excluded from the HPPMCS, as were measurements obtained for patients in CASCADE whose estimated date of infection occurred before 15 years of age.
The incidence rates of death and progression to initial AIDS diagnosis or death were calculated by accumulating person-time according to the most recent CD4 cell count and age at the time of CD4 cell count determination. Follow-up from the time that each measurement was obtained was censored at the earliest of the following points in time: (1) the date of the next measurement; (2) 12 months after the most recent measurement (to account for irregular follow-up); (3) the date of the last clinical visit (for analyses of AIDS or death [AIDS/death]) or the date the patient was last known to be alive (for analyses of death); or (4) 31 December 1995. Before 1996, combination ART was infrequently used in both studies, and our estimates should therefore approximately reflect the natural history of HIV infection. Smooth incidence estimates determined on the basis of CD4 cell counts and age were obtained by fitting separate Poisson regression fractional polynomial models for HPPMCS (limited to measurements obtained after 5 years of age) and CASCADE (Stata software, version 8.2; Stata Corporation) (see table A1 in appendix A, which appears only in the electronic edition of the Journal). Estimates of incidence rates are displayed on a logarithmic scale to show more clearly the effect of age.
RESULTS
A total of 3244 children from the HPPMCS and 3497 adults from CASCADE were included in the analysis. Selected characteristics of the study population are presented in table 1. In the HPPMCS, a mean of 7.1 CD4 cell counts were measured per child before an event or censoring occurred, with a median interval of 12 weeks (interquartile range [IQR], 8 -19 weeks) between successive evaluations; in CASCADE, the corresponding values were 11.1 CD4 cell count measurements and 14 weeks (IQR, 8 -26 weeks). These measurements were performed over a wide age range, spanning from birth to 60 years, although comparatively few measurements were obtained during the period of adolescence.
Progression to death. A total of 595 deaths were observed over 7790 person-years of follow-up in the HPPMCS, compared with 665 deaths observed over 12,710 person-years of follow-up in CASCADE. Crude and smoothed rates of death, as classified by age and the most recent CD4 cell count, are shown in table 2 and figure 1A. For reference, rates for the general male population in England and Wales were also tabulated. Young children (age, Ͻ5 years) had a much higher mortality rate than did older children and adults. For children 5 years of age, a slight decrease in the mortality rate occurred in association with increasing age (1.7% decrease/year of age), after adjustment for most recent CD4 cell count; however, this effect was not significant (95% confidence interval [CI], 9.6% decrease/year of age to 6.7% increase/year of age; P ϭ .7). By contrast, age was strongly associated with mortality among adults, with an increase of 3.1%/year of age (95% CI, 2.4%-3.8%/year of age; P Ͻ .001) noted. Death rates for individuals with CD4 cell counts of Ͻ400 cells/mm 3 were comparable in children 5 years of age and adults ϳ20 years of age, with there being some evidence of a lower risk among children with higher CD4 cell counts. Of note, no deaths were observed among children 5 years of age who had a CD4 cell count of Ͼ350 cells/mm 3 , despite 1306 personyears of follow-up (upper 95% confidence limit, 0.23 death/100 person-years), which is significantly lower than the mortality rate of 0.63 death/100 person-years for patients aged 15-25 years who had the same CD4 cell count (P ϭ .008, by exact 2-sided Poisson test). Among older children and adults of all ages, mortality increased sharply when the CD4 cell count decreased to a level below 150 -200 cells/mm 3 , with 71% of deaths occurring among patients with a CD4 cell count of Ͻ50 cells/mm 3 .
Progression to AIDS/death. A total of 949 children experienced progression to AIDS/death over 5890 person-years of follow-up in the HPPMCS, compared with 945 adults over 11,310 person-years of follow-up in CASCADE. The proportion of patients who died without a reported AIDS diagnosis was similar in the 2 studies: 10.2% (n ϭ 97) in the HPPMCS and 8.9% (n ϭ 84) in CASCADE. The effects of age on progression to AIDS/death, after adjustment for the CD4 cell count, were broadly similar to the effects of age on mortality (table 2) (figure 1b). The incidence of progression to AIDS/death decreased rapidly over early childhood, but the change in incidence noted after 5 years of age (i.e., a 2.7% decrease/year of age [95% CI, 9.4% decrease/year of age to 4.5% increase/year of age]), was not significant (P ϭ .4). In adults, this incidence increased by 1.9%/ year of age (95% CI, 1.3%-2.5% increase/per year of age; P Ͻ .001), which is slightly weaker than the effect of age on mortality. The incidence of progression to AIDS/death among children 5 years of age was within the (broad) range of incidence rates for adults with CD4 cell counts of 150 -300 cells/ mm 3 . At a CD4 cell count of 150 cells/mm 3 , the estimated rate of progression to AIDS/death for a 5-year-old child (12.8 events/ 100 person-years) was similar to that for a 20-year-old adult (13.0 events/100 person-years); at a CD4 cell count of 300 cells/ mm 3 , the estimated rate of progression to AIDS/death for a 5-year-old child (7.1 events/100 person-years) was closer to that noted for a 50-year-old adult (7.3 events/100 person-years). Compared with adults, older children had a lower incidence of AIDS/death at a CD4 cell count of Ͻ150 cells/mm 3 , as well as a higher incidence at a count of Ͼ300 cells/mm 3 .
The interpretation of these analyses is complicated by the different spectrum of AIDS-defining conditions in children and adults (figure 2). For example, Kaposi sarcoma comprised 15.1% of all initial AIDS diagnoses in CASCADE but was not reported in the HPPMCS. Conversely, serious recurrent bacterial infection was the most frequent AIDS diagnosis in the HPPMCS (in 29.7% of patients) but was rare in CASCADE (in 1.8% of patients). This condition occurred among children 5 years of age who had relatively high CD4 cell counts; the median value preceding a diagnosis of AIDS was 250 cells/mm 3 for serious recurrent bacterial infection, 80 cells/mm 3 for wasting syndrome, 54 cells/mm 3 for HIV encephalopathy, and 26 cells/mm 3 for opportunistic infections. Similar findings have been reported elsewhere [14, 15] . Because the marked difference in the relative frequency of serious recurrent bacterial infection between children and adults is partly methodological, we repeated the Poisson regression analysis, with the exception that the diagnosis of serious recurrent bacterial infection was treated as a censoring event. This change substantially reduced the estimated risk of disease progression for children, particularly among those with higher CD4 cell counts (figure 1C), with risk estimates for older children becoming similar to or lower than those for young adults.
DISCUSSION
This analysis of 2 large, prospective studies by use of a common methodology has provided valuable insights into how the association between the CD4 cell count and the rate of disease progression varies according to patient age-from birth to 60 years-in the absence of effective ART. Effect of age. Consistent with a previous report from the HPPMCS, our study found no evidence indicating that, when we control for the most recent CD4 cell count, age affects the shortterm risk of progression to AIDS or death among children 5 years of age [4] . However, confidence intervals around the age coefficients are wide, because estimates are based on data spanning a relatively narrow age range. Younger children experience much higher morbidity and mortality rates, as has been discussed elsewhere [3, 4] . Estimates of rates from CASCADE are more precise and show that age was strongly associated with disease progression in adults, both in terms of AIDS/death (a rate increase of 1.7%/year of age) and death (a rate increase of 3.1%/year of age). Although the latter effect is, in part, a result of the natural increase in mortality independent of HIV infection, this appears to be only a minor factor. The numbers of observed deaths in CASCADE were 7-fold (among patients Ͼ55 years of age) to 30-fold (among patients 15-24 years of age) higher than the predictions derived from statistics for the general population.
Older age at HIV seroconversion has been clearly associated with a shorter period of AIDS incubation and poorer survival expectations [16, 17] . One reason for this is an apparent association between steeper decreases in the CD4 cell count and increasing age [18, 19] . The present study establishes that this effect is coupled with an increased susceptibility to clinical disease at the same level of immunologic suppression.
Comparison of children and adults. A major objective of our analysis was to assess whether there is an age threshold at which the association between the CD4 cell count and the rate of disease progression in children approximates that observed in adults. The presence of a strong effect of age across adulthood indicates that comparisons must be made with reference to specific ages. Children 5 years of age and adults ϳ20 years of age had similar mortality rates at a CD4 cell count of Ͻ350 CD4 cells/mm 3 , with there being some evidence of a lower risk among children with higher CD4 cell counts. A limitation of our study is that we were unable to distinguish HIV-related deaths from non-HIV-related deaths; however, among children, virtually all deaths presumably were of the former type. Studies that collected cause-of-death information in the era before highly active ART estimated that only 7%-13% of deaths occurring among HIV-infected persons during this period were not HIV related [20, 21] , with this proportion presumably increasing at higher CD4 cell counts. We therefore speculate that the apparent difference in mortality between older children and younger adults with high CD4 cell counts is due to non-HIV-related deaths.
An important caveat in the comparison of AIDS incidence rates is the different case definitions used for children and adults/ death rate and the AIDS or death (AIDS/death) rate (per 100 person-years) , by current CD4 cell count and age. adolescents. In particular, serious recurrent bacterial infection is more broadly defined in the case definition of pediatric AIDS. Also, although each diagnosis should be confirmed by culture, some of the reported cases in the HPPMCS are likely to have been only presumptively diagnosed. Our findings were sensitive to whether we included or excluded cases of serious recurrent bacterial infection. If such cases were included, children showed comparatively high rates of disease progression at higher CD4 cell counts, an effect that is partly methodological but may also reflect the lack of preexisting immunity when perinatally infected children are first exposed to bacterial organisms. Conversely, if serious recurrent bacterial infection was excluded, the difference in the rates of disease progression between older children and adults at higher CD4 cell counts was no longer apparent. One justification for placing more emphasis on the latter analysis, aside from the difficulty of a making a secure diagnosis, is evidence that serious recurrent bacterial infection is a relatively weak prognostic indicator of death (HPPMCS, unpublished data). Clinical implications. Current treatment guidelines for adults recommend that ART be initiated when the CD4 cell count is 200 -350 cells/mm 3 [6] ; however, pediatric treatment guidelines tend to be more conservative, recommending ART initiation at higher CD4 cell count levels [7] . A key finding from our analysis is that, although data for the period of adolescence are sparse, children 5 years of age have short-term risks of AIDS and death that are lower than or similar to those for adults with a CD4 cell count in the range for which treatment is usually considered. In particular, no deaths occurred among older children with a CD4 cell count of Ͼ350 cells/mm 3 . Therefore, it would seem logical to achieve consistency between pediatric and adult treatment guidelines, in terms of the CD4 cell count criteria for initiation of ART, although there is important variation in the immunologic and virologic response to ART by age [22] . The CD4 cell count criteria for younger children is more problematic, and there is ongoing debate on the use of the CD4 cell count or CD4 cell percentage for clinical monitoring of this age group, including the question of how discordant values of these markers should be interpreted [4] . Finally, there currently is much interest in conducting an international trial to determine the optimal CD4 cell count thresholds for initiation of ART [23] . Our results indicate that the inclusion of older children would enhance the generalizability of data from such a study, although the possibility of heterogeneous effects associated with age would need to be carefully examined [24] . mophilia Cohort (Caroline Sabin and Christine Lee), the UK Register of HIV Seroconverters (K.P., Anne Johnson, A.P., Abdel Babiker, Janet Darbyshire, and Valerie Delpech), the University College London (Deenan Pillay), and the University of Oxford (Harold Jaffe).
